Barclays raised the firm’s price target on Universal Health (UHS) to $263 from $250 and keeps an Overweight rating on the shares post the Q3 report. The firm says that when excluding items, Universal Health’s Q3 EBITDA would have been closer to $634M, which is about 7.5% better than the most comparable estimate of $590M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Closing Bell Movers: Rambus slips 9%, F5 down 6% after Q3 earnings
- Universal Health reports Q3 adjusted EPS $5.69, consensus $4.95
- Universal Health raises FY25 adj EPS view to $21.50-$22.10 from $20.00-$21.00
- Notable companies reporting after market close
- UHS Earnings Report this Week: Is It a Buy, Ahead of Earnings?